title: Polyphenon E: a new treatment for external anogenital warts.
abstract: Background External genital warts (EGWs, condylomata acuminata) are a common, highly contagious disease caused by human papillomavirus (HPV), predominantly HPV 6 and HPV 11. Green tea catechins have been identified for their immunostimulatory, antiproliferative and antitumour properties. Two phase III trials evaluated treatment of EGWs with ointment containing a mixture of green tea catechins (Polyphenon E), U.S. adopted name: sinecatechins). Objectives To obtain additional data on the efficacy and safety of Polyphenon E ointment in the treatment of EGWs from two randomized, double-blind, vehicle-controlled trials. Methods Men and women aged > or = 18 years (n = 1005), with two to 30 EGWs (12-600 mm(2) total area) applied vehicle (G(Veh); n = 207), Polyphenon E ointment 10% (G(10%); n = 401) or Polyphenon E ointment 15% (G(15%); n = 397) three times daily until complete clearance of all EGWs (baseline + new EGWs) or for a maximum of 16 weeks. Results A total of 1004 patients were evaluable for safety and 986 for efficacy; 838 completed treatment after 16 weeks. Complete clearance of all EGWs was obtained in 53.6% (G(10%)) and 54.9% (G(15%)) of patients with Polyphenon E vs. vehicle (35.4%) (P < 0.001). Statistically significant differences in clearance rates appeared after 6 weeks of active treatment. Odds ratios vs. G(Veh) for G(10%) [2.10; 95% confidence interval (CI) 1.49-2.98] and G(15%) (2.22; 95% CI 1.57-3.14) indicated about a twofold higher chance of complete clearance under active treatment. Time to complete clearance was shorter with active treatment (hazard ratios 1.57 and 1.87, respectively, for G(10%) and G(15%) vs. G(Veh) groups; P < 0.001). Recurrence rates during follow-up were low and similar across groups: 5.8%, 6.8% and 6.5% (G(Veh), G(10%) and G(15%) groups, respectively). Adverse events were evenly distributed across groups ( approximately 30% of patients). Severe local signs were more frequent but moderate in the active treatment groups (1.5%, 9.2% and 13.5% for G(Veh), G(10%) and G(15%) groups, respectively). Conclusions Polyphenon E ointment is effective and well tolerated in the treatment of EGWs.
authors.affiliation: The Hospital Clinicas, Universidad de Buenos Aires, Av. Cordoba 2351, Buenos Aires 1120, Argentina.
authors.forename: S
authors.initials: S
authors.lastname: Tatti
authors.forename: E
authors.initials: E
authors.lastname: Stockfleth
authors.forename: K R
authors.initials: KR
authors.lastname: Beutner
authors.forename: H
authors.initials: H
authors.lastname: Tawfik
authors.forename: U
authors.initials: U
authors.lastname: Elsasser
authors.forename: P
authors.initials: P
authors.lastname: Weyrauch
authors.forename: A
authors.initials: A
authors.lastname: Mescheder
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001004:Anus Diseases / Q000188:drug therapy*; D002392:Catechin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003218:Condylomata Acuminata / Q000188:drug therapy; D004311:Double-Blind Method; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D005832:Genital Diseases, Male / Q000188:drug therapy*; D006801:Humans; D008297:Male; D028321:Plant Preparations / Q000008:administration & dosage / Q000009:adverse effects; D014860:Warts / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D028321:Plant Preparations; D002392:Catechin; C472086:polyphenon E